Abstract
INTRODUCTION: Undifferentiated prostate cancer is a rare and aggressive disease, and no definitive therapeutic strategy for metastatic undifferentiated prostate cancer has been established. CASE PRESENTATION: We report the case of a 70-year-old man with undifferentiated prostate cancer and lymph node metastases. Following the patient's progression after platinum-based chemotherapy, we initiated treatment with docetaxel, which resulted in a partial response. The patient was alive for 42 months after initiation of docetaxel, maintaining relatively good quality of life with minimal hospital stay. CONCLUSION: Docetaxel may be a good therapeutic option for metastatic undifferentiated prostate cancer.